Abstract
Matrix metalloproteinase 1 (MMP-1) is necessary for degradation of interstitial collagen types I, II, and III, which are the major constituents of the extracellular matrix (ECM). Increased expression of MMP-1 has been correlated with invasiveness of certain malignancies and cartilage degradation in rheumatoid arthritis. Increased transcriptional activity of MMP-1 has been reported with a single nucleotide polymorphism (SNP) of the MMP-1 promoter. Systemic sclerosis (SSc) is characterized by increased accumulation and turnover of collagen and other components of ECM. Previous studies have reported increased expression of MMP-1 transcripts in SSc fibroblasts. Therefore, we sought to determine if SSc patients with early disease (⩽5 years) from a multi-ethnic cohort were more or less likely than ethnically-matched normal controls to have an increased frequency of the high promoter activity MMP-1 genotype and whether MMP-1 promoter genotypes correlated with any of the major clinical manifestations of SSc. The results show that the frequency of the high activity promoter genotype in either the heterozygous or homozygous state did not differ significantly between SSc patients and ethnically-matched controls, or between SSc patients with either diffuse or limited scleroderma. Furthermore, MMP-1 promoter genotypes did not significantly correlate with any of the major clinical manifestations of SSc.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 6 digital issues and online access to articles
$119.00 per year
only $19.83 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Trojanowska M, Leroy EC, Eckes B, Krieg T Pathogenesis of fibrosis: type I collagen and the skin J Mol Med 1998 76 266–274
Jimenez SA, Hitraya E, Varga J Pathogenesis of scleroderma. Collagen Rheum Dis Clin North Am 1996 22 647–674
Borden P, Heller R Transcriptional control of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases Crit Rev Eukaryotic Gene Expres 1997 7 159–178
MacDougall JR, Matrisian LM Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis Cancer Metastasis Rev 1995 14 351–362
Yoshihara Y, Nakamura H, Obata K et al Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis Ann Rheum Dis 2000 59 455–461
Kuroda K, Shinkai H Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis Arch Dermatol Res 1997 289 567–572
Xiaodong Z, Tan FK, Xiong M, Milewicz DM, Arnett FC Comparisions of fibroblasts gene expression profiles in systemic sclerosis, normal controls, scleromyxedema, and eosinophilic fasciitis Arthritis Rheum 2000 41 (Suppl) S259 (Abst. 1154)
Rutter JL, Mitchell TF, Buttice G et al A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter create an ets binding site and augments transcription Cancer Res 1998 58 5321–5325
Reveille JD, Fischbach M, McNearney T et al Systemic sclerosis in three ethnic groups: a combination of clinical, sociodemogrphic, serologic and immunogentic determinants Semin Arthritis Rheum 2001 30 332–346
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee Preliminary criteria for the classification of systemic sclerosis (scleroderma) Arthritis Rheum 1980 23 581–590
LeRoy EC, Black C, Fleischmajer R et al Scleroderma (systemic sclerosis): classification, subsets and pathogenesis J Rheumatol 1988 2 202–205
Clements P, Lachenbruch P, Seibold JR et al Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis J Rheumatol 1995 22 1281–1285
Arnett FC, Reveille JD, Goldstein R et al Autoantibodies to fibrillarin in systemic sclerosis (scleroderma): an immunogenetic, serologic, and clinical analysis Arthritis Rheum 1996 39 1151–1160
Uria JA, Jimenez MG, Balbin M, Freije JMP, Lopez-Otin C Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts J Biol Chem 1998 273 9769–9777
Rutter JL, Benhow U, Coon CI, Brinkerhoff CE Cell-type specific regulation of human interstitial collagenase-1 gene expression by interleukin-1β (IL-1β) in human fibroblasts and BC-8701breast cancer cells J Cell Biochem 1997 66 322–336
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from NIAMS: Specialized Center for Research in Scleroderma Award IP50AR44888, the RGK Foundation, and the LASR Fund to Dr Arnett and NIH:NCRR 3M01 RR02558–12S1 to Dr Tan.
Rights and permissions
About this article
Cite this article
Johnson, R., Reveille, J., McNearney, T. et al. Lack of association of a functionally relevant single nucleotide polymorphism of matrix metalloproteinase-1 promoter with systemic sclerosis (scleroderma) . Genes Immun 2, 273–275 (2001). https://doi.org/10.1038/sj.gene.6363768
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gene.6363768
Keywords
This article is cited by
-
Matrix Metalloproteinases: A Review of Their Structure and Role in Systemic Sclerosis
Journal of Clinical Immunology (2012)
-
The single nucleotide polymorphisms of matrix metalloproteinase-1 in patients with systemic sclerosis
Rheumatology International (2008)
-
The genetics of systemic sclerosis
Current Rheumatology Reports (2002)